Mark R. Wills

10.3k total citations · 3 hit papers
114 papers, 5.8k citations indexed

About

Mark R. Wills is a scholar working on Epidemiology, Immunology and Infectious Diseases. According to data from OpenAlex, Mark R. Wills has authored 114 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Epidemiology, 56 papers in Immunology and 27 papers in Infectious Diseases. Recurrent topics in Mark R. Wills's work include Cytomegalovirus and herpesvirus research (72 papers), Immune Cell Function and Interaction (41 papers) and Herpesvirus Infections and Treatments (32 papers). Mark R. Wills is often cited by papers focused on Cytomegalovirus and herpesvirus research (72 papers), Immune Cell Function and Interaction (41 papers) and Herpesvirus Infections and Treatments (32 papers). Mark R. Wills collaborates with scholars based in United Kingdom, United States and Portugal. Mark R. Wills's co-authors include J. G. P. Sissons, Sarah Jackson, Michael P. Weekes, Kim Mynard, John Sinclair, Andrew Carmichael, Georgina Okecha, Emma Poole, A.J. Carmichael and Gavin M. Mason and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Journal of Clinical Investigation.

In The Last Decade

Mark R. Wills

111 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL

1996 605 citations Mark R. Wills, A.J. Carmichael et al. profile →
Ribosome Profiling Reveals Pervasive Translation Outside of Annotated Protein-Coding Genes

2014 480 citations Sarah Jackson, Mark R. Wills et al. profile →
Spontaneous, persistent, T cell–dependent IFN-γ release in patients who progress to Long Covid

2024 41 citations Benjamin A. Krishna, Eleanor Y. Lim et al. Science Advances profile →

Peers

Countries citing papers authored by Mark R. Wills

Since Specialization

Citations

This map shows the geographic impact of Mark R. Wills's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Wills with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Wills more than expected).

Fields of papers citing papers by Mark R. Wills

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Wills. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Wills. The network helps show where Mark R. Wills may publish in the future.

Co-authorship network of co-authors of Mark R. Wills

This figure shows the co-authorship network connecting the top 25 collaborators of Mark R. Wills. A scholar is included among the top collaborators of Mark R. Wills based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark R. Wills. Mark R. Wills is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Robust antibody and T cell responses tracked longitudinally in patients with long COVID 2025 ·Journal of General Virology ·(unknown), Raja Ram, Marianne Perera, Mark R. Wills, Benjamin A. Krishna, Nyaradzai Sithole	0
2	Spontaneous, persistent, T cell–dependent IFN-γ release in patients who progress to Long Covid breakdown → 2024 ·Science Advances ·Benjamin A. Krishna, Eleanor Y. Lim, (unknown), Sarah Jackson, Lenette Mactavous, (unknown), Paul Lyons, Rainer Döffinger, John R. Bradley, Kenneth G. C. Smith, John Sinclair, Nicholas J. Matheson, Paul J. Lehner, Nyaradzai Sithole, Mark R. Wills	41
3	Comparison of different T cell assays for the retrospective determination of SARS-CoV-2 infection 2024 ·Journal of General Virology ·Benjamin A. Krishna, (unknown), Marianne Perera, Mark R. Wills, Nyaradzai Sithole	1
4	Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID 2022 ·EBioMedicine ·Benjamin A. Krishna, Eleanor Y. Lim, (unknown), Paul Lyons, Rainer Döffinger, John R. Bradley, Kenneth G. C. Smith, John Sinclair, Nicholas J. Matheson, Paul J. Lehner, Mark R. Wills, Nyaradzai Sithole	24
5	HCMV carriage in the elderly diminishes anti-viral functionality of the adaptive immune response resulting in virus replication at peripheral sites 2022 ·Frontiers in Immunology ·Emma L. Davies, (unknown), Eleanor Y. Lim, Charlotte J. Houldcroft, Georgina Okecha, Claire Atkinson, Matthew B. Reeves, Sarah Jackson, Mark R. Wills	6
6	Using Primary Human Cells to Analyze Human Cytomegalovirus Biology 2021 ·Methods in molecular biology ·Emma Poole, Ian J. Groves, Sarah Jackson, Mark R. Wills, John Sinclair	11
7	Killer cell proteases can target viral immediate-early proteins to control human cytomegalovirus infection in a noncytotoxic manner 2020 ·PLoS Pathogens ·(unknown), Shuang Li, Jan Meeldijk, Bernadet Blijenberg, (unknown), (unknown), (unknown), Ian J. Groves, Martin Potts, (unknown), Thomas Stamminger, Mark R. Wills, Niels Bovenschen	9
8	A novel, sensitive dual-indicator cell line for detection and quantification of inducible, replication-competent latent HIV-1 from reservoir cells 2019 ·Scientific Reports ·Fanny Salasc, David W. Gludish, Isobel Jarvis, Saikat Boliar, Mark R. Wills, David G. Russell, Andrew Lever, Hoi Ping Mok	4
9	Utilizing TAPBPR to promote exogenous peptide loading onto cell surface MHC I molecules 2018 ·Proceedings of the National Academy of Sciences ·(unknown), Andreas Neerincx, Mark R. Wills, Maike de la Roche, Louise H. Boyle	28
10	Innovations in the quantitative virus outgrowth assay and its use in clinical trials 2017 ·Retrovirology ·(unknown), Axel Fun, (unknown), Mark R. Wills, Hoi Ping Mok, Andrew Lever	6
11	Human Cytomegalovirus Delays Neutrophil Apoptosis and Stimulates the Release of a Prosurvival Secretome 2017 ·Frontiers in Immunology ·Joanna Pocock, Daniel M. L. Storisteanu, Matthew B. Reeves, Jatinder K. Juss, Mark R. Wills, Andrew S. Cowburn, Edwin R. Chilvers	25
12	Transient activation of human cytomegalovirus lytic gene expression during latency allows cytotoxic T cell killing of latently infected cells 2016 ·Scientific Reports ·Benjamin A. Krishna, Betty Lau, Sarah Jackson, Mark R. Wills, John Sinclair, Emma Poole	47
13	How understanding immunology contributes to managing CMV disease in immunosuppressed patients: now and in future 2015 ·Medical Microbiology and Immunology ·J. G. P. Sissons, Mark R. Wills	32
14	A novel neuroprotective therapy for Parkinson’s disease using a viral noncoding RNA that protects mitochondrial Complex I activity 2011 ·The Journal of Experimental Medicine ·Wei‐Li Kuan, Emma Poole, Michael Fletcher, Sharon Karniely, Pam Tyers, Mark R. Wills, Roger A. Barker, John Sinclair	32
15	Immune evasion proteins gpUS2 and gpUS11 of human cytomegalovirus incompletely protect infected cells from CD8 T cell recognition 2009 ·Virology ·(unknown), Mark R. Wills, Bodo Plachter	41
16	Rapid CD8+ T Cell Repertoire Focusing and Selection of High-Affinity Clones into Memory Following Primary Infection with a Persistent Human Virus: Human Cytomegalovirus 2007 ·The Journal of Immunology ·Elizabeth Day, Andrew Carmichael, Ineke J. M. ten Berge, (unknown), J. G. P. Sissons, Mark R. Wills	109
17	Long-Term Stable Expanded Human CD4+ T Cell Clones Specific for Human Cytomegalovirus Are Distributed in Both CD45RAhigh and CD45ROhigh Populations 2004 ·The Journal of Immunology ·Michael P. Weekes, Mark R. Wills, J. G. P. Sissons, Andrew Carmichael	37
18	Identification of Naive or Antigen-Experienced Human CD8+ T Cells by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8+ T Cell Response 2002 ·The Journal of Immunology ·Mark R. Wills, Georgina Okecha, Michael P. Weekes, Maher K. Gandhi, Patrick Sissons, Andrew Carmichael	184
19	Vaccines against persistent DNA virus infections 2002 ·British Medical Bulletin ·Mark R. Wills, A.J. Carmichael, J. G. P. Sissons	7
20	Large clonal expansions of human virus‐specific memory cytotoxic T lymphocytes within the CD57⁺ CD28^– CD8⁺ T‐cell population 1999 ·Immunology ·Michael P. Weekes, Mark R. Wills, Kim Mynard, Ray Hicks, J. G. P. Sissons, A.J. Carmichael	108

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact